1285499-91-3Relevant articles and documents
A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors
Lee, Wendy,Ortwine, Daniel F.,Bergeron, Philippe,Lau, Kevin,Lin, Lichuan,Malek, Shiva,Nonomiya, Jim,Pei, Zhonghua,Robarge, Kirk D.,Schmidt, Stephen,Sideris, Steve,Lyssikatos, Joseph P.
, p. 5097 - 5104 (2013/09/12)
A series of N-7-methyl-imidazolopyrimidine inhibitors of the mTOR kinase have been designed and prepared, based on the hypothesis that the N-7-methyl substituent on imidazolopyrimidine would impart selectivity for mTOR over the related PI3Kα and δ kinases. The corresponding N-Me substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines also show potent mTOR inhibition with selectivity toward both PI3α and δ kinases. The most potent compound synthesized is pyrazolo[4,3-d]pyrimidine 21c. Compound 21c shows a Ki of 2 nM against mTOR inhibition, remarkable selectivity (>2900×) over PI3 kinases, and excellent potency in cell-based assays.
